Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06254950 · ClinicalTrials.gov registry record · Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2 study of Ulcerative Colitis, sponsored by Takeda.

Recruiting
Registry status
Phase 2
Development phase
207
Enrollment target
20
Study locations

NCT06254950 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Takeda. The registered enrollment target is 207 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06254950, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 2
Development phase
207 participants
Enrollment target
20
Study locations

Study Summary

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.

Conditions Studied

Ulcerative Colitis

Interventions

  • DRUG Placebo
  • DRUG TAK-279

Study Locations (20)

Florida

  • West Central Gastroenterology, LLP, d/b/a/ Gastro Florida - Clearwater
  • Auzmer Research - Lakeland
  • GI PROS, Inc. - Naples
  • USF Health Morsani Center for Advanced Healthcare - Tampa

California

  • GastroIntestinal BioSciences - Los Angeles
  • United Medical Doctors - Murrieta

Georgia

  • Emory University Hospital, The Emory Clinic - Atlanta
  • Atlanta Center For Gastroenterology, P.C. - Decatur

Texas

  • Novel Research, LLC - Bellaire
  • Tyler Research Institute, LLC - Tyler

South Australia

  • Flinders Medical Centre - Bedford Park
  • The Queen Elizabeth Hospital - Woodville

Kentucky

  • University Of Louisville - Louisville

Maryland

  • Woodholme Gastroenterology Associates - Glen Burnie

Nevada

  • Las Vegas Medical Research - Las Vegas

Trial Details

FieldValue
Enrollment Target 207 participants
Start Date 2024-03-29
Est. Completion 2027-08-04
Phase Phase 2

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06254950

The ClinicalTrials.gov registry entry for NCT06254950 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (90% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06254950 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06254950 about?

NCT06254950 is a clinical study titled "A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis". The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take caps...

What is the current status of trial NCT06254950?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2024-03-29. Estimated completion is 2027-08-04.

What conditions does trial NCT06254950 study?

This clinical trial studies the following conditions: Ulcerative Colitis.

What interventions are being tested in trial NCT06254950?

The interventions under investigation include: Placebo (DRUG), TAK-279 (DRUG).

Who is sponsoring clinical trial NCT06254950?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06254950 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.